Pharmacologic management of heart failure and left ventricular systolic dysfunction: effect in female, black, and diabetic patients, and cost-effectiveness.
P
P
Shekelle
S
S
Morton
S
S
Atkinson
M
M
Suttorp
W
W
Tu
P
P
Heidenreich
M
M
Gubens
M
M
Maglione
L
L
Jungvig
E
E
Roth
S
S
Newberry
D000319:Adrenergic beta-Antagonists / Q000191:economics / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000191:economics / Q000627:therapeutic use*; D044383:Black People / Q000706:statistics & numerical data*; D003362:Cost-Benefit Analysis; D048909:Diabetes Complications; D005260:Female; D006333:Heart Failure / Q000188:drug therapy* / Q000191:economics; D006801:Humans; D008297:Male; D013599:Systole; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy* / Q000191:economics
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors